Popular Articles
Teeth Whitening Products

Access Pharmaceuticals Provides Update On ProLindac(TM) Phase 2 Ovarian Cancer Trial And Clinical Development Plan
ACCESS PHARMACEUTICALS, INC.(OTC Bulletin Board: ACCP), provided an update on the progress in the Company"s clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies. Access recently announced positive safety and efficacy results from its Phase 2 monotherapy clinical study of ProLindac(TM) in late-stage, heavily pretreated ovarian cancer patients. In this study, 66% of patients who received the highest dose achieved clinically meaningful disease stabilization according to RECIST criteria. No patient in any dose group exhibited any signs of acute neurotoxicity, which is a major adverse side-effect of the approved DACH platinum, Eloxatin, and ProLindac was well tolerated overall. The Company has scaled up manufacturing in order to begin the next phase of clinical development. Access plans to conduct several combination trials in different solid tumor types both as Company-sponsored trials and in conjunction with its two previously announced co-development partners.
generic viagra online
Moving To The U.S. Increases Cancer Risk For Hispanics
Results of a new study confirm trends that different Hispanic population groups have higher incidence rates of certain cancers and worse cancer outcomes if they live in the United States, than they do if they live in their homelands.
News of the day
One In Seven Young Canadian Adults Deficient In Vitamin C, Study Finds
One in seven young adults in Canada is deficient in vitamin C, according to a first-of-its kind study published today. The findings, published in the American Journal of Epidemiology, suggest that young adults with a vitamin C (ascorbic acid) deficiency have significantly higher waist circumference, body mass index, inflammation and blood pressure - indicators of chronic disease and obesity - than do people with adequate blood levels of vitamin C.
Mental Health

Recent Releases: PEPFAR And IDUs; Economic Crisis And Health; Human-Rights And Pharmaceutical Companies

Lancet Commentary Examines How PEPFAR Failing To Reach IDUs Although PEPFAR has helped to provide "antiretroviral therapy to 2.1 million people with HIV, almost all of whom live in sub-Saharan Africa, and has spent more than US$18 billion on the continent" it has failed to reach "thousands of injecting drug users in PEPFAR countries in Africa, many of whom have HIV," according to the authors of a recent comment in the journal Lancet. The authors conclude, "PEPFAR has a rare opportunity to save many lives in Africa by encouragement and funding of effective strategies for HIV prevention and treatment for drug users, initiatives that have been in place in much of the world for a long time (Csete/Gathumbi/Wolfe, Lancet, 6/13). Research Needed On Effect Of "Economic Crisis" On Global Health Andy Robertson, the editor-in-chief of Emerging Health Threats Journal, writes in an editorial that the potential effects of the economic downturn on health "have received much less attention" but are likely to be "manifold." "At a global level, health care, already precarious in many developing countries, is likely to decline further as aid dries up and government expenditure falls, with millions more forced into poverty and malnutrition, particularly women and children," Robertson writes. He concludes by recommending that "urgent research and critical analysis are necessary to look into the impact that this economic crisis is having on health in both developed and developing countries, and into identifying solutions than may ameliorate the most detrimental effects of this potential healthcare disaster" (Robertson, Emerging Health Threats Journal, 6/9). Editorial Examines Right-To-Health Responsibilities Of Pharmaceutical Companies An editorial appearing in the journal Lancet examines the recommendations that came out of a recent human rights report on the practices and policies of pharmaceutical company GlaxoSmithKline (GSK) "in relation to their right-to-health responsibilities and access to medicines" and GSK"s reaction to the analysis. The editorial concludes, "Pharmaceutical companies help deliver the right to health. They save lives. But with this role comes responsibilities - and companies must be better held to public account in relation to those responsibilities. The 2008 guidelines and the GSK report move us closer to that goal" (Lancet, 6/13). To read GSK"s response to the report, click here (GlaxoSmithKline statement, 6/09). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):